Samsca is owned by Otsuka.
Samsca contains Tolvaptan.
Samsca has a total of 2 drug patents out of which 0 drug patents have expired.
Samsca was authorised for market use on 19 May, 2009.
Samsca is available in tablet;oral dosage forms.
The generics of Samsca are possible to be released after 07 April, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8501730||OTSUKA||Process for preparing benzazepine compounds or salts thereof|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10905694||OTSUKA||Pharmaceutical solid preparation comprising benzazepines and production method thereof|| |
(7 years from now)
Market Authorisation Date: 19 May, 2009
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic